EMBER: A Study of LY3484356 in Patients with Breast or Other Non-Breast Cancers - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if a new investigational drug called LY3484356 (study drug) is a safe and effective treatment for metastatic ER+/HER2+ breast cancer. We will combine the study drug with either trastuzumab or trastuzumab + abemaciclib in the study.
Metastatic ER+/HER2+ Breast Cancer
Who Can Participate in the Study?
- Are diagnosed with metastatic ER+/HER2+ breast cancer
- Experienced worsening of disease when taking endocrine therapy
For more information about who can join this study, please contact the study team at 919-660-1278.
What is Involved?
If you choose to join this study you will:
- Be randomly assigned (like a coin flip) to 1 of 2 groups
-- One group will take the study drug with trastuzumab
-- The other group will take the study drug with trastuzumab and abemaciclib
- Have physical exams
- Have blood draws
- Have imaging scans
The study drug and abemaciclib are taken by mouth daily during the treatment period. Trastuzumab is given as an infusion once every 21 days during the treatment period.
You will return to our clinic after your treatment ends for follow-up visits to see how you are doing.